3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
14
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
3
Immunologic Deficiency Syndromes
2
Thalassemia
1
Neoplasms
1
Myelodysplastic Syndromes
1
Muscle Neoplasms
1
Metabolic Diseases
1
Melanoma
1
Lymphoma
1
Hemoglobinopathies
1
Hematologic Neoplasms
1
Fanconi Anemia
1
Chronic Pain
1
Breast Neoplasms
1
Anemia, Sickle Cell
1
Anemia, Aplastic
1
Interventions
Surveys and Questionnaires
70
Blood Specimen Collection
60
palbociclib
37
Trastuzumab
31
Letrozole
26
Immunohistochemistry
26
Drug Therapy
24
Anastrozole
24
Radiotherapy
21
Gene Expression Profiling
20
Amplified Fragment Length Polymorphism Analysis
20
Mastectomy, Segmental
19
Biopsy
19
Tamoxifen
18
exemestane
17
Interviews as Topic
17
ribociclib
16
Mastectomy
16
Fulvestrant
16
Paclitaxel
15
Magnetic Resonance Spectroscopy
15
Psychiatric Rehabilitation
14
High-Energy Shock Waves
14
Polymerase Chain Reaction
13
Observation
13
Microarray Analysis
13
Capecitabine
13
trastuzumab deruxtecan
12
Neoadjuvant Therapy
12
Specimen Handling
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Breast Neoplasms
×
Melphalan
×
Clear all
NCT06154590
2023-12-04
NASBP-B-09
Paradyne Networks A Foundation
Not yet recruiting
100 enrolled